Myocarditis and mRNA COVID-19 vaccines 2026: signal, data, and interpretation

In 2021, surveillance systems in multiple countries detected a safety signal for myocarditis and pericarditis after mRNA COVID‑19 vaccination, particularly in adolescent and young adult males. Three years later, the data are much more robust: the risk is real but rare, lower with updated formulations and longer intervals, and the clinical course is generally mild with good medium‑term outcomes. For most age‑risk groups, the benefit–risk balance of mRNA vaccination remains clearly favorable. Here is the GHP data synthesis 2025–26. The original safety signal: what was seen? Multiple sources converged in 2021–22: Passive surveillance (e.g., VAERS) and active systems such as the US Vaccine Safety Datalink (VSD) identified increased rates of myocarditis/pericarditis within about 7 days after mRNA vaccination, with the highest incidence after the second dose of the primary series in males aged 12–24 years.1-3 Early VSD analyses estimated crude reporting rates in young males of roughly tens of cases per million doses after...